DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023
| Authors | |
|---|---|
| Year of publication | 2023 |
| MU Faculty or unit | |
| Web | RASMIR |
| Description | Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study. |